河南中医2026，Vol.46Issue(1)：21-28,8.DOI:10.16367/j.issn.1003-5028.2026.01.0004
基于"态靶辨证"理论探讨药对治疗溃疡性结肠炎研究进展
Research Progress on Drug Pairs for Treating Ulcerative Colitis Based on the Theory of"State-Target Syndrome Differentiation"
摘要
Abstract
The main symptoms of ulcerative colitis(UC),such as diarrhea,bloody stools,and abdominal pain,can be regarded as"symptom targets."Under the theory of state-target syndrome differentiation,the selection of drugs for these symptom targets should ad-here as closely as possible to the principle of state classification.Similarly,when applying drug pairs to hit these targets,this principle should be followed to leverage the strength of TCM in providing individualized treatment.Specifically,for the three major"symptom tar-gets"of UC,corresponding drug pairs have demonstrated unique therapeutic effects:Buguzhi(Fructus Psoraleae)-Roudoukou(Semen Myristicae)pair exhibits specific efficacy against UC-related diarrhea by warming the kidney and spleen,and consolidating the intestines to stop diarrhea.Sanqi(Radix et Rhizoma Notoginseng)-Baiji(Rhizoma Bletillae)pair shows promising potential for UC-related bloody stools by stopping bleeding without causing blood stasis,and promoting wound healing while protecting the intestinal collaterals.Yan-husuo(Rhizoma Corydalis)-Baizhi(Radix Angelicae Dahuricae)pair has application value for UC-related abdominal pain by unblock-ing collaterals to relieve pain.Currently,research on drug pairs for treating UC faces the following problems:(1)At the"symptom tar-get"level,UC is a Western medical disease name,differing from the TCM disease-naming system based on symptoms like"consumptive disease."Whether these TCM symptoms can serve as precise"symptom targets"for UC treatment,along with their scientific connota-tion and corresponding relationships,urgently needs clarifying.(2)Regarding research content,existing literature predominantly focuses on the molecular mechanisms of drug pairs,while clinical validation of their synergistic effects and efficacy evaluation for specific symp-toms remain relatively weak.Therefore,future research should shift toward higher-level clinical and transformation applications.On the one hand,high-quality clinical and animal studies are needed to deeply explore the synergistic rules and"symptom target"potential of drug pairs for UC.On the other hand,attention should be paid to new opportunities brought by appropriate TCM techniques.Rectal ad-ministration routes such as enemas and suppositories,etc.not only significantly enhance the biological availability of certain drugs,but also open new avenues for drug pair research.关键词
溃疡性结肠炎/"态靶辨证"/"症靶"/药对/补骨脂-肉豆蔻/三七-白及/延胡索-白芷分类
医药卫生引用本文复制引用
QIAN Li,FAN Wenbin,DOU Yuanqun,HUANG Yi..基于"态靶辨证"理论探讨药对治疗溃疡性结肠炎研究进展[J].河南中医,2026,46(1):21-28,8.基金项目
重庆市璧山区科技局2024年社会民生领域科学计划项目(BSKJ2024080) （BSKJ2024080）
